6 February 2016

Rusoro looks at London

Robert Tyerman

Hugo Chavez, a friend of potential AIM entrant Rusoro Mining. Picture: Agencia Brasil

Hugo Chavez, a friend of potential AIM entrant Rusoro Mining. Picture: Agencia Brasil

Andre Agapov, boss of Canada-quoted Rusoro Mining, is thinking of dangling its Venezuelan gold prospects before London investors.

Rusoro, now listed at the equivalent of 22.5p on the junior Toronto Venture Exchange, claims potential resources of 17 million ounces of gold in the oil-rich South American republic’s El Callao, El Dorado and Cuyuni districts, with two million oz at 3.5 grammes of gold per tonne of ore in the proven and probable category. The company’s Choco project, sold to it by major South African mining group Goldfields in exchange for a 26.4 per cent stake, is set to show it has exceeded target production of 170,000 oz for this year at a cash cost, before capital and financing expenses, now down to $322 an ounce, against today’s market price of nearly $965.

Agapov, whose father Vladimir is chairman and major shareholder in Rusoro and on friendly terms with Venezuela’s controversial president Hugo Chavez, says the company aims to produce 500,000 oz of gold a year from Choco alone by 2012, but will need £125 million to progress its projects. He and Rusoro’s president George Salamis point out it has £34 million cash and £50 million convertible debt in place, some of it from Russian gold miner Peter Hambro Mining, and hint the company could seek access to the new Russo-Venezuelan development bank – but indicate they are also thinking of a London listing to test the UK equity market.

The entrepreneurial Andre Agapov, who says his own earlier dispute with the Thai government over the Bangkok Bank of Commerce was satisfactorily resolved, argues the Chavez regime is not as hostile to foreign mining companies as many, especially in the USA, believe. He acknowledges a long-running dispute over the future ownership of Venezuela’s Las Cristinas gold mine has done little to reassure overseas investors, but insists Rusoro has always been able to secure acceptable terms.

Tags: AIM, Fundraisings, New Issues

Cash Shells 2015

Published in September 2015 this annual research report provides a comprehensive overview of cash shells on the Main Market, AIM and PLUS landscape. Order your copy today

 

Superb investment toolkit for private investors

SharePad is the new web-based service from ShareScope. Easier to use and more powerful. Perfect for tablets, Macs and Windows PC. Covers ALL your investment requirements.

Growth Company Investor: free trial

Since 2008, our share tips outperformed the benchmark by 281%. Take a free trial and get access to our recommendations today. Start free trial now.

Directors' Pay on AIM 2015

The most comprehensive review of AIM directors' pay available, and this year includes a record sample of 1000+ AIM-quoted companies. The full report is available to order for £385 + VAT. Click here for more info

 

Latest small-cap and growth company news

Daily coverage of small-cap company stocks on London's junior markets AIM and PLUS, breaking news, stock research and latest share price information for investors. Full sector coverage with all the latest news on smaller listed companies, updated several times a day with financial reports, trading statements and links to further web resources.

Popular News

Latest News

Forbidden focuses on selling

Forbidden Technologies (AIM: FBT) has been around a long time but has failed to generate much in the way of revenues, despite having a product that sounds like it should be a winner. There were board changes last year and new CEO Aziz Musa is shifting resources towards selling and away from technological development. This has to be the right strategy and we should find out if it’s working as this year unfolds.

Wash those nits right out of your hair!

Tyratech (AIM: TYRU) offers a compelling product proposition. Controlling bugs and parasites using conventional pesticides is both harmful to the environment and ineffective. Over the years insects have built up resistance to many of the chemicals used to kill them. So Tyratech’s natural products are not only safer but also a lot more effective than the competition. 

Angling for a cancer breakthrough

Results from medical device manufacturer Angle (AIM: AGL) showed its innovative Parsortix system to be nicely on track. The first commercial sales for research use have just been made and three leading cancer centres are moving forward with trials that will support its clinical use in the diagnosis of ovarian cancer.

2016 Quoted Company Award Winners announced

The 12th annual Grant Thornton Quoted Company Awards took place this week at the Natural History Museum in London. This prestigious event is organised by Growth Company Investor and is a celebration of the success and achievements of the UK’s smaller company sector. We published the shortlisted nominees for each award category earlier in January; so read on to see who the winners were...

Plexus hammered by oil industry shutdown

In the middle of 2014 Plexus (AIM: POS) was riding high with a share price of 320p giving the company a market value of £270 million. Today’s profit warning has seen the shares slump 40 per cent to just 73p, valuing Plexus at a mere £65 million. As an engineering company selling mainly into the oil industry, we shouldn’t be too surprised by downgrades. But the severity is startling.

Fusionex shares plunge on hidden profit warning

Malaysian big data software specialist Fusionex (AIM: FXI) has released an upbeat results statement for the year to September. As well as beating historic forecasts, the new financial year is said to have started “on a very strong note… the outlook for 2016 and beyond is very positive”. Sounds fantastic! Yet by this afternoon the shares had collapsed by 35 per cent.

More News